Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-60
SponsorAlexandria University
About this trial
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age: 20-60 years, both sexes.
ASA physical status class I to III.
BMI 35-50 kg/m²
Disqualifiers
Severe cardiac disorder
chronic renal failure
liver cirrhosis
major psychological disorder
Trial design
Design model
Parallel
Treatments tested in this trial
Enoxaparin
Drug40mg
rivaroxaban
Drug10mg
Treatment groups
162 Participants
are divided into 2 treatment groupsGroup A: group EActive comparator 1 intervention
Group B: group RExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Incidence of thromboembolic events
deep vein thrombosis, pulmonary thromboembolism, mesenteric vascular occlusion
Time frame
month 3 postoperativeSecondary outcomes
1
incidence of postoperative bleeding
hematemisis, melena
Time frame
one month postoperative2
incidence of reoperation
number
Time frame
month 3 postoperative3
incidence of readmission
number
Time frame
month 3 postoperative4
patient satisfaction using likert scale
1: extremely dissatisfied, 2: dissatisfied, 3: neutral, 4: satisfied, and 5: extremely satisfied 1: extremely dissatisfied, 2: dissatisfied, 3: neutral, 4: satisfied, and 5: extremely satisfied 1: extremely dissatisfied, 2: dissatisfied, 3: neutral, 4: satisfied, and 5: extremely satisfied
Time frame
month 3 postoperativeSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov